gemfibrozil has been researched along with Chronic Kidney Failure in 14 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This was a post hoc subgroup analysis in the Veterans Affairs High-Density Lipoprotein Intervention Trial, a randomized double-blind trial of gemfibrozil versus placebo in 2,531 men with coronary disease, HDL-C levels of 40 mg/dL or less (< or =1." | 9.11 | Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. ( Bloomfield, H; Collins, D; Curhan, GC; Robins, S; Tonelli, M, 2004) |
| "To present a case of gemfibrozil-induced myositis which precipitated an acute compartment syndrome." | 7.68 | Acute compartment syndrome: an unusual presentation of gemfibrozil induced myositis. ( Chow, LT; Chow, WH, 1993) |
| "Severe rhabdomyolysis complicated by respiratory and renal failure developed three weeks after initiation of low dose lovastatin therapy in a 79 year old, non-immunocompromised patient." | 7.68 | Lovastatin-induced acute rhabdomyolysis. ( Kogan, AD; Orenstein, S, 1990) |
| "A 49-year-old woman with chronic renal failure was given gemfibrozil for hyperlipidemia." | 5.29 | Gemfibrozil induced myositis: a case report with light microscopic and ultrastructural study. ( Chow, LT; Chow, WH, 1994) |
| "This was a post hoc subgroup analysis in the Veterans Affairs High-Density Lipoprotein Intervention Trial, a randomized double-blind trial of gemfibrozil versus placebo in 2,531 men with coronary disease, HDL-C levels of 40 mg/dL or less (< or =1." | 5.11 | Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. ( Bloomfield, H; Collins, D; Curhan, GC; Robins, S; Tonelli, M, 2004) |
| "To present a case of gemfibrozil-induced myositis which precipitated an acute compartment syndrome." | 3.68 | Acute compartment syndrome: an unusual presentation of gemfibrozil induced myositis. ( Chow, LT; Chow, WH, 1993) |
| " In 55 patients (20 on HD, 13 on CAPD and 22 NDCRF) with severe hypertriglyceridemia or diminished HDL cholesterol gemfibrozil 300 mg b." | 3.68 | Lipid abnormalities in chronic uremic patients. Response to treatment with gemfibrozil. ( Dardamanis, MA; Elisaf, MS; Papagalanis, ND; Siamopoulos, KC, 1993) |
| "Severe rhabdomyolysis complicated by respiratory and renal failure developed three weeks after initiation of low dose lovastatin therapy in a 79 year old, non-immunocompromised patient." | 3.68 | Lovastatin-induced acute rhabdomyolysis. ( Kogan, AD; Orenstein, S, 1990) |
| "Gemfibrozil treatment significantly reduces both plasma lipids and apoB, apoC-III and apoE concentrations in patients with moderately advanced renal insufficiency." | 2.68 | Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease. ( Alaupovic, P; Attman, PO; Knight-Gibson, C; Kron, B; Larsson, R; Mulec, H; Samuelsson, O; Weiss, L, 1997) |
| "Eighteen patients with chronic renal failure (serum creatinine 173-756 mumol/l) and hyperlipidemia were treated with gemfibrozil (1200 mg/day)." | 2.66 | Normalization of lipoprotein lipase and hepatic lipase by gemfibrozil results in correction of lipoprotein abnormalities in chronic renal failure. ( Korte, T; Kuusi, T; Pasternack, A; Solakivi, T; Vänttinen, T, 1987) |
| "Hyperlipidemia is a well-recognized complication of renal transplantation." | 2.38 | Hyperlipidemia and transplantation: etiologic factors and therapy. ( Belzer, FO; D'Alessandro, AM; Kalayoglu, M; Knechtle, SJ; Pirsch, JD; Reed, A; Sollinger, HW, 1992) |
| "A 49-year-old woman with chronic renal failure was given gemfibrozil for hyperlipidemia." | 1.29 | Gemfibrozil induced myositis: a case report with light microscopic and ultrastructural study. ( Chow, LT; Chow, WH, 1994) |
| "A 61-year-old woman with hyperlipidemia was treated with gemfibrozil." | 1.29 | [Gemfibrozil-induced myopathy]. ( Adler, Y; Aron, A; Weiss, P, 1993) |
| "Patients with chronic renal failure appear at greater risk for skeletal muscle side effects from the fibric acid group of lipid lowering agents." | 1.29 | Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure. ( Irish, A; Kemp, GJ; Radda, GK; Taylor, DJ; Thompson, CH, 1996) |
| "Gemfibrozil was determined in plasma and urine by means of a HPLC method." | 1.28 | Gemfibrozil absorption and elimination in kidney and liver disease. ( Knauf, H; Kölle, EU; Mutschler, E, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 10 (71.43) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tonelli, M | 2 |
| Collins, D | 2 |
| Robins, S | 2 |
| Bloomfield, H | 2 |
| Curhan, GC | 2 |
| Dogra, G | 1 |
| Irish, A | 2 |
| Chan, D | 1 |
| Watts, G | 1 |
| Chow, LT | 2 |
| Chow, WH | 2 |
| Aron, A | 1 |
| Adler, Y | 1 |
| Weiss, P | 1 |
| Elisaf, MS | 1 |
| Dardamanis, MA | 1 |
| Papagalanis, ND | 1 |
| Siamopoulos, KC | 1 |
| Thompson, CH | 1 |
| Kemp, GJ | 1 |
| Taylor, DJ | 1 |
| Radda, GK | 1 |
| Akçiçek, F | 1 |
| Ok, E | 1 |
| Duman, S | 1 |
| Kürsad, S | 1 |
| Unsal, A | 1 |
| Alev, M | 1 |
| Atabay, G | 1 |
| Basçi, A | 1 |
| Samuelsson, O | 1 |
| Attman, PO | 1 |
| Knight-Gibson, C | 1 |
| Kron, B | 1 |
| Larsson, R | 1 |
| Mulec, H | 1 |
| Weiss, L | 1 |
| Alaupovic, P | 1 |
| Pirsch, JD | 1 |
| D'Alessandro, AM | 1 |
| Sollinger, HW | 1 |
| Knechtle, SJ | 1 |
| Reed, A | 1 |
| Kalayoglu, M | 1 |
| Belzer, FO | 1 |
| Knauf, H | 1 |
| Kölle, EU | 1 |
| Mutschler, E | 1 |
| Kogan, AD | 1 |
| Orenstein, S | 1 |
| Pasternack, A | 1 |
| Vänttinen, T | 1 |
| Solakivi, T | 1 |
| Kuusi, T | 1 |
| Korte, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase IV, Single Center Pilot Study Using Alemtuzumab (Campath-1H) Induction Combined With Prednisone-Free, Calcineurin-Inhibitor-Free Immunosuppression in Kidney Transplantation[NCT00166712] | Phase 4 | 40 participants (Actual) | Interventional | 2005-04-30 | Terminated (stopped due to Study stopped due to lack of efficacy & funding.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The incidence of rejection is determined by the proportion of patients experiencing biopsy proven acute allograft rejection during the first 12 months post-transplant. (NCT00166712)
Timeframe: Within 12 months post kidney transplant
| Intervention | Participants (Number) |
|---|---|
| Groups | 4 |
| Group 2 | 6 |
1 review available for gemfibrozil and Chronic Kidney Failure
| Article | Year |
|---|---|
Hyperlipidemia and transplantation: etiologic factors and therapy.
Topics: Adrenal Cortex Hormones; Antihypertensive Agents; Coronary Disease; Diuretics; Gemfibrozil; Humans; | 1992 |
6 trials available for gemfibrozil and Chronic Kidney Failure
| Article | Year |
|---|---|
Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency.
Topics: Aged; Cardiovascular Diseases; Creatinine; Gemfibrozil; Humans; Hypolipidemic Agents; Incidence; Kid | 2004 |
Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease.
Topics: Aged; Cholesterol, HDL; Confounding Factors, Epidemiologic; Coronary Disease; Double-Blind Method; F | 2004 |
A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD.
Topics: Adult; Aged; Atorvastatin; Brachial Artery; Double-Blind Method; Elasticity; Endothelium, Vascular; | 2007 |
Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study.
Topics: Adult; Aged; Cholesterol; Combined Modality Therapy; Cross-Over Studies; Diet, Fat-Restricted; Femal | 1996 |
Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease.
Topics: Apolipoproteins; Cholesterol; Female; Gemfibrozil; Glomerular Filtration Rate; Humans; Hypolipidemic | 1997 |
Normalization of lipoprotein lipase and hepatic lipase by gemfibrozil results in correction of lipoprotein abnormalities in chronic renal failure.
Topics: Adult; Aged; Clinical Trials as Topic; Enzyme Activation; Female; Gemfibrozil; Humans; Kidney Failur | 1987 |
7 other studies available for gemfibrozil and Chronic Kidney Failure
| Article | Year |
|---|---|
Gemfibrozil induced myositis: a case report with light microscopic and ultrastructural study.
Topics: Biopsy; Female; Gemfibrozil; Humans; Kidney Failure, Chronic; Middle Aged; Mitochondria, Muscle; Mus | 1994 |
[Gemfibrozil-induced myopathy].
Topics: Diabetes Complications; Female; Gemfibrozil; Humans; Hyperlipidemias; Kidney Failure, Chronic; Middl | 1993 |
Acute compartment syndrome: an unusual presentation of gemfibrozil induced myositis.
Topics: Acute Disease; Biopsy; Compartment Syndromes; Female; Gemfibrozil; Humans; Hyperlipidemias; Kidney F | 1993 |
Lipid abnormalities in chronic uremic patients. Response to treatment with gemfibrozil.
Topics: Adult; Aged; Cholesterol, HDL; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; H | 1993 |
Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure.
Topics: Adult; Aged; Cholesterol; Exercise; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agen | 1996 |
Gemfibrozil absorption and elimination in kidney and liver disease.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Female; Gemfibrozil; Half-Life; Humans; Intestina | 1990 |
Lovastatin-induced acute rhabdomyolysis.
Topics: Acute Disease; Age Factors; Aged; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Kidney Fai | 1990 |